Pharmaceutical composition for preventing or treating cancer
Extracellular vesicles from Faecalibacterium strains address the limitations of current cancer treatments by targeting cancer cells effectively and reducing side effects, enhancing anticancer efficacy when used alone or in combination with conventional therapies.
Patent Information
- Application Number
- JP2024532798
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-01-19
- Filing Date
- 2023-02-15
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current cancer treatments, such as chemotherapy and radiation therapy, have severe side effects on normal cells and often lead to drug resistance in cancer cells, while combination therapies with immune checkpoint inhibitors and probiotics have limited research and effectiveness.
A pharmaceutical composition containing extracellular vesicles derived from Faecalibacterium strains, particularly Faecalibacterium prausnitzii, which can be administered alone or in combination with chemical or immunological anticancer agents to target cancer cells, reducing tumor growth and metastasis while minimizing side effects.
The composition effectively reduces tumor size, inhibits angiogenesis, and enhances anticancer effects when combined with conventional treatments, overcoming the limitations of existing therapies by activating the immune system and specifically targeting cancer cells.
Smart Images

Figure 2024544663000001_ABST
Abstract
Description
[Technical field]
[0001] The present invention relates to a pharmaceutical composition for preventing or treating cancer, and more specifically, to a pharmaceutical composition for preventing or treating cancer comprising extracellular vesicles (EVs) derived from a Faecalibacterium strain. [Background technology]
[0002] Cancer is the product of uncontrolled and unregulated cell proliferation caused by an excess of abnormal cells. Malignant tumors have the property of growing rapidly by leaving the primary site and invading other tissues, thus threatening life.
[0003] In order to treat cancer, various therapeutic approaches have been attempted, such as chemotherapy using various anticancer drugs, radiation therapy, and antibody therapy targeting specific in vivo molecules related to cancer. However, chemotherapy and radiation therapy have severe side effects because they also affect normal cells, and cancer cells acquire resistance to the anticancer drugs, so treatment often fails or recurs.
[0004] Recent research reports have shown that extracellular vesicles play an important role in processes such as intercellular signaling and waste management, and interest in their clinical application has been growing recently. By utilizing the properties of specific extracellular vesicles and the cell membrane of target cells, it is expected that it will be possible to develop therapeutic drugs that can prevent side effects on other normal cells and specifically treat only diseased cells, including cancer cells.
[0005] Meanwhile, the importance of research into the combined therapy of probiotics, which have beneficial effects on the body such as strengthening the immune system, and immune checkpoint inhibitors has been emphasized in the field of pharmabiotics. However, research into this topic for various cancers has been very limited. Summary of the Invention [Problem to be solved by the invention]
[0006] The present invention is intended to solve the above-mentioned technical problems, and an object of the present invention is to provide a pharmaceutical composition for preventing or treating cancer, comprising extracellular vesicles derived from pharmacobiotics.
[0007] Another object of the present invention is to provide a health functional food for preventing or improving cancer.
[0008] It is yet another object of the present invention to provide a veterinary composition or feed additive for the prevention or treatment of cancer or inflammatory diseases.
[0009] Yet another object of the present invention is to provide a method for treating cancer in a patient by activating the patient's immune system with pharmacobiotic-derived extracellular vesicles. [Means for solving the problem]
[0010] In order to achieve the above object, one aspect of the present invention is to The present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising extracellular vesicles (EVs) derived from a Faecalibacterium sp. strain and a pharma- ceutically acceptable carrier or excipient.
[0011] The Faecalibacterium strain may be a Faecalibacterium prausnitzii strain, preferably Faecalibacterium prausnitzii EB-FPDK3 strain (KCCM12619P), F. prausnitzii EB-FPDK9 strain (KCCM12620P), F. prausnitzii EB-FPDK11 strain (KCCM12621P), or F. prausnitzii EB-FPYYK1 strain (KCCM12622P).
[0012] The pharmaceutical composition for preventing or treating cancer of the present invention may further comprise a cancer therapeutic agent such as a chemical anticancer agent or an immune anticancer agent. The immune anticancer agent may be selected from the group consisting of anti-PD1, anti-PDL1, anti-CTLA, anti-Tim3 and anti-LAG3. The extracellular vesicles (EVs) derived from Faecalibacterium sp. strain and the chemical anticancer agent or the immune anticancer agent may be administered simultaneously in one dosage form, or may be administered simultaneously or sequentially in separate dosage forms.
[0013] Another aspect of the present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising a Faecalibacterium strain and a pharma- ceutically acceptable carrier or excipient.
[0014] Another aspect of the present invention relates to a health functional food for preventing or improving cancer, comprising extracellular vesicles (EVs) derived from a Faecalibacterium strain and a physiologically acceptable carrier or excipient.
[0015] Another aspect of the present invention relates to a method for treating cancer, comprising administering to a subject a therapeutically effective amount of a Faecalibacterium strain or extracellular vesicles (EVs) derived from a Faecalibacterium strain.
[0016] Another aspect of the present invention relates to a veterinary composition for preventing or treating cancer comprising a Faecalibacterium strain, or extracellular vesicles (EVs) derived from a Faecalibacterium strain, and an acceptable carrier or excipient.
[0017] The present invention provides novel F. prausnitzii EB-FPDK3 strain (KCCM12619P), F. prausnitzii EB-FPDK9 strain (KCCM12620P), F. prausnitzii EB-FPDK11 strain (KCCM12621P), and F. prausnitzii EB-FPYYK1 strain (KCCM12622P). Effect of the Invention
[0018] The Faecalibacterium strain of the present invention or a pharmaceutical composition for preventing or treating cancer comprising extracellular vesicles (EVs) derived from a Faecalibacterium strain can be developed as an effective anti-cancer drug by reducing tumor size, reducing tumor growth, preventing metastasis, and preventing angiogenesis.
[0019] The pharmaceutical composition for preventing or treating cancer comprising the Faecalibacterium strain of the present invention or extracellular vesicles (EVs) derived from a Faecalibacterium strain not only exhibits excellent anti-cancer effects when administered alone, but also, when administered in combination with a chemical anti-cancer agent or an immunological anti-cancer agent, reduces the side effects of the anti-cancer agent and further activates its efficacy, thereby providing even more excellent anti-cancer effects than when these are administered alone. [Brief description of the drawings]
[0020] [Figure 1] 1 shows the results of microscopic observation of the Faecalibacterium prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 strains of the present invention and the type strain, Faecalibacterium prausnitzii A2-165 type strain. [Diagram 2] 1 shows the results of PCR analysis of the Faecalibacterium prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 strains of the present invention and the standard Faecalibacterium prausnitzii A2-165 strain. [Diagram 3]RAPD (Random Amplified Polymorphic DNA) analysis results of genomic DNA of the Faecalis bacterium prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 strains of the present invention and the Faecalis bacterium prausnitzii A2-165 standard strain. [Figure 4] Phylogenetic diagram of F. prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 strains based on 16S rRNA sequences. [Diagram 5] The results of confirming whether or not the hemolytic activity of the Faecalibacterium prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 strains of the present invention and the standard Faecalibacterium prausnitzii A2-165 strain is retained are shown. [Figure 6] Electron microscope photographs of extracellular vesicles derived from the F. prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 strains of the present invention. [Figure 7a] Figures 7a and 7b are schematic diagrams illustrating the animal experimental process of Examples 4 and 5 to confirm the anti-cancer activity of the F. prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 strains of the present invention alone or extracellular vesicles (EVs) derived from the strains. [Figure 7b]Figures 7a and 7b are schematic diagrams illustrating the animal experimental process of Examples 4 and 5 to confirm the anti-cancer activity of the F. prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 strains of the present invention alone or extracellular vesicles (EVs) derived from the strains. [Figure 8] Figures 8 and 9 show the tumor formation-inhibitory effect of combined administration of the F. prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 strains of the present invention and aPD-1 in mice with allogeneic tumor transplants. [Figure 9] Figures 8 and 9 show the tumor formation-inhibitory effect of combined administration of the F. prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 strains of the present invention and aPD-1 in mice with allogeneic tumor transplants. [Figure 10] Photographs comparing tumor size in mice in each experimental group for 20 days in an allograft anti-cancer animal model to measure the cancer development-suppressing effect of combined administration of the Faecalibacterium prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 strains of the present invention and aPD-1 antibody in Example 4. [Figure 11] In Example 5, this is a graph showing the change in tumor size over time in an allograft anti-cancer animal model to measure the cancer development-suppressing effect of extracellular vesicles derived from the F. prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 strains of the present invention. [Figure 12] This is a graph showing the change in tumor weight over 25 days when extracellular vesicles derived from F. prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 strains were administered together with anti-PD1 and when anti-PD1 alone was administered in an allograft anti-cancer animal model. [Figure 13] These are photographs comparing the tumor sizes of mice in each experimental group over 25 days in an allograft anti-cancer animal model to measure the cancer development-suppressing effect of extracellular vesicles derived from the F. prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 strains of the present invention. [Figure 14a] Figures 14a and 14b show the results of evaluating the anticancer activity of extracellular vesicles derived from the F. prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 strains of the present invention using a wound healing assay in HT29 cells. [Figure 14b] Figures 14a and 14b show the results of evaluating the anticancer activity of extracellular vesicles derived from the F. prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 strains of the present invention using a wound healing assay in HT29 cells. [Figure 15] This is a schematic diagram showing the scheme of animal experiments to confirm the anti-cancer effect of administration of Faecalibacterium prausnitzii EB-FPDK9 or EB-FPDK9-derived extracellular vesicles (EB-FPDK9 EVs) in an allograft mouse animal model using melanoma. [Figure 16]Tumor growth curves are shown when Faecalibacterium prausnitzii EB-FPDK9 strain or EB-FPDK9 EVs were administered. [Figure 17] These are photographs comparing tumor size at the end of administration of Faecalibacterium prausnitzii EB-FPDK9 strain or EB-FPDK9 EVs. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0021] The present invention will now be described in more detail with reference to the accompanying drawings.
[0022] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0023] In this specification, when a part is said to "comprise," "have," or "contain" a certain element, this does not mean to exclude other elements, but means that other elements may be further included, unless specifically stated to the contrary.
[0024] As used herein, the terms "treat," "treatment," and the like refer to temporarily or permanently relieving a symptom, removing the cause of a symptom, or preventing or delaying the onset of a symptom of a disease or condition.
[0025] The term "prevention" as used herein means any action of suppressing or delaying cancer by administration of a pharmaceutical composition according to the present invention.
[0026] As used herein, the term "amelioration" refers to any action that reduces a parameter associated with an abnormal condition, such as the severity of a symptom.
[0027] As used herein, the term "pharmacologically acceptable" means a composition that is suitable for use in contact with the tissues of a subject (e.g., a human) without excessive toxicity, irritation, allergic response, or other problem or complication, with a reasonable benefit / risk ratio, and within the scope of sound medical judgment.
[0028] As used herein, the term "immune checkpoint inhibitor" refers to a class of drugs that block specific proteins produced by certain types of immune system cells, such as T lymphocytes, and some cancer cells; these proteins suppress the immune response and prevent T lymphocytes from killing cancer cells. Well-known "immune checkpoint inhibitors" to date include PD-1 / PD-L1 and CTLA-4 / B7-1 / B7-2.
[0029] One aspect of the present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising extracellular vesicles (EVs) derived from a Faecalibacterium sp. strain and a pharma- ceutically acceptable carrier or excipient.
[0030] Pharmabiotics are defined as bacteria or products of human origin that have a proven pharmacological role in health or disease ("Probiotics and pharmabiotics", Bioeng Bugs. 2010 Mar-Apr; 1(2): 79-84.). The pharmaceutical composition of the present invention is based on a pharmacobiotic component and can be used safely without side effects.
[0031] The Faecalibacterium strain may be a Faecalibacterium prausnitzii strain. Specifically, the Faecalibacterium strain may be a Faecalibacterium prausnitzii EB-FPDK3 strain (KCCM12619P), a F. prausnitzii EB-FPDK9 strain (KCCM12620P), a F. prausnitzii EB-FPDK11 strain (KCCM12621P), or a F. prausnitzii EB-FPYYK1 strain (KCCM12622P).
[0032] Extracellular vesicles (EVs) are nano-sized vesicles secreted by cells that contain immunologically important proteins such as main histocompatibility complex (MHC) and heat shock proteins to induce strong anti-tumor immune responses, as well as anti-inflammatory microRNAs and microRNAs that regulate collagen accumulation.
[0033] The extracellular vesicles (EVs) derived from the Faecalibacterium sp. strain of the present invention simultaneously exhibit the effects of inhibiting cancer cell proliferation, reducing cancer cell mobility, and inhibiting angiogenesis, and can be used as excellent anticancer agents, and can be administered in combination with existing chemical anticancer agents or immune anticancer agents.
[0034] Another aspect of the present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising a Faecalibacterium sp. strain and a pharma- ceutically acceptable carrier or excipient. The strain may be live or killed.
[0035] The Faecalibacterium strain of the present invention, or extracellular vesicles (EVs) derived from a Faecalibacterium strain, may be administered simultaneously with the chemical anticancer agent or immunoanticancer agent as a single formulation, or may be administered simultaneously or sequentially as separate formulations.
[0036] In the present invention, the method for separating extracellular vesicles is not limited, and for example, in a culture medium, separation can be performed using methods such as centrifugation, ultra-high speed centrifugation, filtration with a filter, gel filtration chromatography, preflow electrophoresis, capillary electrophoresis, separation using a polymer, and combinations thereof, and preferably, separation can be performed by centrifugation / ultracentrifugation. In this case, centrifugation / ultracentrifugation can be performed sequentially at 100 to 300,000 g, preferably 150 to 150,000 g, to remove cell debris, non-extracellular vesicle fractions, dead cells, etc.
[0037] Differential centrifugation The most preferred method for the separation of extracellular vesicles is differential centrifugation. This method consists of several steps, is preferably carried out at about 4° C., and includes at least the following three steps, step 1) to step 3): Step 1) Low speed centrifugation to remove cells and cell debris; Step 2) a high speed spin to remove large vesicles >100 nm; and Step 3) High speed centrifugation to pellet extracellular vesicles.
[0038] Density gradient centrifugation : This approach combines ultracentrifugation with sucrose density gradient. More specifically, density gradient centrifugation is used to separate extracellular vesicles from non-decellular particles, such as proteins and protein / RNA aggregates. Thus, this method separates vesicles from particles of other densities.
[0039] Size Exclusion Chromatography Size Exclusion Chromatography is used to separate macromolecules based on their size, rather than their molecular weight. This technique applies a column packed with porous polymer beads containing multiple pores and tunnels. Molecules pass through the beads according to their diameter. Molecules with smaller radii take longer to move through the pores of the column, so the macromolecules elute from the column sooner. Size Exclusion Chromatography allows for the precise separation of large and small molecules.
[0040] filtration Ultrafiltration membranes can also be used to isolate extracellular vesicles. Depending on the size of the microvesicles, this method allows the isolation of extracellular vesicles from proteins and other macromolecules.
[0041] Polymer-based precipitation : Polymer-based precipitation methods generally involve mixing the biological fluid with a polymer-containing precipitation solution, incubation at 4°C, and centrifugation at low speed. One of the most common polymers used in polymer-based precipitation is polyethylene glycol (PEG). Precipitation with this polymer has many advantages, including its mild effect on isolated extracellular vesicles and the use of a neutral pH.
[0042] Isolation by sieving : This technique isolates extracellular vesicles by sieving them from biological fluids through a membrane and performing filtration by pressure or electrophoresis.
[0043] The pharmaceutical composition of the present invention has excellent effects in preventing or treating cancer.
[0044] Specifically, Faecalibacterium strains, or extracellular vesicles derived from Faecalibacterium strains, are inhaled by cancer cells, suppress EMT, and activate the immune system to suppress the penetration and metastasis of cancer cells.
[0045] Preferably, the Faecalibacterium strain may be Faecalibacterium prausnitzii EB-FPDK3 strain, F.prausnitzii EB-FPDK9 strain, F.prausnitzii EB-FPDK11 strain, or F.prausnitzii EB-FPYYK1 strain. Preferably, the extracellular vesicles derived from the Faecalibacterium strain may be Faecalibacterium prausnitzii EB-FPDK3 strain, Faecalibacterium prausnitzii EB-FPDK9 strain, Faecalibacterium prausnitzii EB-FPDK11 strain, or Faecalibacterium prausnitzii EB-FPYYK1 strain. Hereinafter, these extracellular vesicles are abbreviated as EB-FPDK3 EV, EB-FPDK9 EV, EB-FPDK11 EV, and EB-FPYYK1 EV, respectively. These EB-FPDK3 EV, EB-FPDK9 EV, EB-FPDK11 EV, and EB-FPYYK1 EV play an important role in regulating T cells to activate the innate and acquired immune systems. In addition, regulatory T cells (Tregs), characterized by the expression of Foxp3, are known to suppress anti-cancer immunity and interfere with protective immune surveillance of tumors, thus opposing effective anti-tumor immune responses. However, EB-FPDK3 EV, EB-FPDK9 EV, EB-FPDK11 EV, and EB-FPYYK1 EV are presumed to exhibit anti-cancer effects by activating T helper cells to activate cytotoxic T cells and suppressing Treg cells. As a result, the pharmaceutical composition of the present invention has excellent effects in preventing, treating, and inhibiting metastasis of cancer.
[0046] As used herein, the term "cancer" is meant to include tumors, neoplasias, and malignant tissues or cells, including colorectal cancer, lung cancer, small cell lung cancer, gastric cancer, liver cancer, blood cancer, bone cancer, pancreatic cancer, skin cancer, head or neck cancer, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, perianal cancer, colon cancer, breast cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, esophageal cancer, small intestine cancer, endocrine gland cancer, thyroid cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, lymphocytic lymphoma, bladder cancer, kidney cancer, ureteral cancer, renal cell carcinoma, renal pelvic cancer, CNS tumor, primary CNS lymphoma, spinal cord tumor, brain stem glioma, pituitary adenoma, or a combination of two or more of these cancers.
[0047] In the present invention, the extracellular vesicles (EVs) derived from the Faecalibacterium strain according to the present invention contained as an active ingredient in the pharmaceutical composition have a size of 20 to 300 nm.
[0048] The effective amount of the pharmaceutical composition according to the present invention may vary depending on the age, sex, and body weight of the patient. In general, 0.001 to 150 mg, preferably 0.01 to 100 mg per kg of body weight is administered every day or every other day, or once to three times a day.
[0049] The pharmaceutical composition according to the present invention can be used as a single anti-cancer therapy. Also, the pharmaceutical composition according to the present invention can be used simultaneously, separately or sequentially with a radiation or chemical anti-cancer agent or an immunological anti-cancer agent, depending on the situation. The combination therapy according to the present invention is for use in at least one of reducing tumor size, predicting tumor growth, preventing metastasis, and preventing angiogenesis.
[0050] Specifically, the pharmaceutical composition of the present invention may be administered sequentially or simultaneously with conventional radiotherapy or anticancer drug therapy. It may also be administered once or multiple times. Taking into account all of the above factors, it is important to administer the minimum amount that provides maximum efficacy without side effects.
[0051] In some embodiments, the immunotherapeutic agent is an immune checkpoint inhibitor. Immune checkpoint inhibition broadly refers to inhibiting checkpoints that cancer cells can produce to prevent or downregulate immune responses. Examples of immune checkpoint proteins include, but are not limited to, CTLA4, PD-1, PD-L1, PD-L2, A2AR, B7-H3, B7-H4, BTLA, KIR, LAG3, TIM-3, or VISTA. The immune checkpoint inhibitor can be an antibody or an antigen-binding fragment thereof that binds to and inhibits the immune checkpoint protein. Examples of immune checkpoint inhibitors include, but are not limited to, nivolumab, pembrolizumab, pidilizumab, AMP-224, AMP-514, STI-A1110, TSR-042, RG-7446, BMS-936559, MEDI-4736, MSB-0020718C, AUR-012, and STI-A1010.
[0052] Unlike conventional chemotherapies that directly kill cells, immune checkpoint inhibitors have been in the spotlight as next-generation anticancer drugs that cause fewer side effects from anticancer chemotherapy, such as hair loss, anemia, and bone marrow suppression, which reduce the quality of life of cancer patients. However, immune checkpoint inhibitors have a very low response rate to some cancers (e.g., gastric cancer, colon cancer, ovarian cancer, pancreatic cancer, etc.), and are known to cause severe immune-related abnormal reactions such as enteritis, hepatitis, pneumonia, hypothyroidism, and hypophysitis. Side effects of using immune checkpoint inhibitors are mainly minor, but in rare cases, they have been reported to be serious and fatal when they occur in the nervous system or cardiac system. The pharmaceutical composition containing extracellular vesicles derived from the Faecalibacterium sp. strain of the present invention can overcome the response rate limit of immune checkpoint inhibitors, minimize side effects, and enhance anticancer effects.
[0053] The F. prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 used in the present invention were isolated from the feces of healthy Korean individuals, and are oval cells measuring 0.5-1 μm in size, monococcus or diplococcus, anaerobic, non-motile, Gram-negative, non-endospore-forming, mucin-degrading bacteria. Faecalibacterium prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 strains are capable of using mucus as a carbon and nitrogen source by producing several mucus-degrading enzymes and are able to metabolize a variety of carbon sources, including glucose, galactose, N-acetylglucosamine, and lactose, producing short-chain fatty acids, such as propionic acid and acetic acid, as major metabolic products.
[0054] In the pharmaceutical composition for preventing or treating cancer of the present invention, the Faecalibacterium strain can be selected from among the strain's bacterial bodies, disrupted bacterial bodies, a culture of the strain, a culture medium in which the bacterial bodies have been removed from the culture of the strain, an extract of the strain's bacterial bodies, an extract of the culture of the strain, or an extract of the culture medium in which the bacterial bodies have been removed from the culture of the strain.
[0055] The Faecalibacterium strain of the present invention may be a live or killed strain. The Faecalibacterium prausnitzii EB-FPDK3, F.prausnitzii EB-FPDK9, F.prausnitzii EB-FPDK11, and F.prausnitzii EB-FPYYK1 strains of the present invention can be cultured, recovered by a separation process such as centrifugation, and manufactured as a live agent by drying, for example, freeze-drying, for use. The killed bacteria can be killed by heat treatment, or inactivated strains that have been pasteurized. Pasteurization of the Faecalibacterium prausnitzii strain means heating at a temperature of 50°C or higher and lower than 100°C for 10 minutes or more. For example, pasteurization can be performed at 70°C for 30 minutes.
[0056] In the present invention, the term "killed bacteria" refers to bacteria that have been sterilized by heating, pressurization, chemical treatment, or the like. There is no particular limitation on the method for producing killed bacteria, so long as it is a method for killing lactic acid bacteria known in the art. As an example, the killed bacteria of the present invention may be produced by a method for killing bacteria that includes heat treatment (by heat treatment). The heat treatment may be performed only on live bacteria separated from a culture solution, or on a culture solution containing the live bacteria. The temperature for the heat treatment is not particularly limited as long as it maintains the properties of the bacteria and sterilizes other general bacteria, but may be 80°C to 150°C, and may be preferably 80°C to 110°C.
[0057] In one embodiment of the present invention, pharmaceutical compositions containing extracellular vesicles derived from the genus Faecalibacterium strain, or the Faecalibacterium prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 strains can be formulated and used in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, or aerosols, topical preparations, suppositories, or sterile injection solutions by conventional methods, but are not necessarily limited to these.
[0058] In some embodiments, pharmaceutical compositions of the present invention include, but are not necessarily limited to, aqueous liquid dispersions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid forms, powders, immediate release formulations, controlled release formulations, fast melt formulations, tablets, capsules, pills, delayed release formulations, sustained release formulations, pulsatile release formulations, multiparticulate formulations, and mixed immediate and controlled release formulations.
[0059] The pharmaceutical composition of the present invention can be used in the form of an aqueous suspension, an isotonic saline solution, or a sterile injectable solution containing a pharmacologically compatible dispersant and / or wetting agent for intravenous administration, intratumoral administration, or intranasal administration. As an excipient, water, alcohol, polyol, glycerol, vegetable oil, etc. can be used.
[0060] The pharmaceutical composition of the present invention can be formulated as a product for enteral or oral administration. In addition, the pharmaceutical composition of the present invention can be enterically coated by a known method so that the active ingredient, extracellular vesicles (EVs), can be rapidly released in the intestine after passing through the stomach and reaching the small intestine.
[0061] The pharmaceutical composition of the present invention may further contain a pharma- ceutically acceptable carrier and / or excipient in addition to the active ingredient, and may be formulated with various additives commonly used in pharmaceuticals, such as binders, disintegrants, coating agents, lubricants, etc.
[0062] The pharma- ceutically acceptable carrier may further include, for example, a carrier for oral administration or a carrier for parenteral administration. Carriers for oral administration include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. In addition, various drug delivery substances used for oral administration may be included. Carriers for parenteral administration may also include water, suitable oils, saline, aqueous glucose, and glycols, and the like. The pharmaceutical composition of the present invention may further include a stabilizer and a preservative. Suitable stabilizers include antioxidants such as sodium bisulfite, sodium sulfite, or ascorbic acid. Suitable preservatives include benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol. The pharma- ceutically acceptable carriers and formulations that may be included in the pharmaceutical composition of the present invention may be referred to in the following documents (Remington's Pharmaceutical Sciences, 1999, pp. 111-115, 2001). th ed., Mack Publishing Company, Easton, PA, 1995).
[0063] Excipients that can be used in the present invention include sugars such as sucrose, lactose, mannitol, glucose, etc., and starches such as corn starch, potato starch, rice starch, partially pregelatinized starch, etc. Binders include polysaccharides such as dextrin, sodium alginate, carrageenan, guar gum, acacia, agar, etc., natural macromolecular substances such as tragacanth, gelatin, gluten, etc., cellulose derivatives such as hydroxypropyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, ethyl cellulose, hydroxypropyl ethyl cellulose, sodium carboxymethyl cellulose, etc., and polymers such as polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl acetate, polyethylene glycol, polyacrylic acid, polymethacrylic acid, and vinyl acetate resins.
[0064] Examples of disintegrants that can be used in the present invention include cellulose derivatives such as carboxymethylcellulose, calcium carboxymethylcellulose, and low-substituted hydroxypropylcellulose, and starches such as sodium carboxymethyl starch, hydroxypropyl starch, corn starch, potato starch, rice starch, and partially pregelatinized starch.
[0065] Examples of lubricants that can be used in the present invention include talc, stearic acid, calcium stearate, magnesium stearate, colloidal silica, hydrous silicon dioxide, various types of waxes and hydrogenated oils.
[0066] Examples of coating agents include, but are not limited to, water-insoluble copolymers such as dimethylaminoethyl methacrylate-methacrylic acid copolymer, polyvinyl acetal diethylamino acetate, ethyl acrylate-methacrylic acid copolymer, ethyl acrylate-methyl methacrylate-chlorotrimethylammonium ethyl methacrylate copolymer, and ethyl cellulose, methacrylic acid-ethyl acrylate copolymer, enteric polymers such as hydroxypropyl methylcellulose phthalate and hydroxypropyl methylcellulose acetate succinate, and water-soluble polymers such as methylcellulose, hydroxypropyl methylcellulose, polyvinylpyrrolidone, and polyethylene glycol.
[0067] The dosage of the extracellular vesicles derived from the Faecalibacterium sp. strain as an active ingredient in the pharmaceutical composition for preventing or treating cancer of the present invention can be determined based on various disease types, the age, weight, sex, medical condition of the patient, the severity of the condition, sensitivity to drugs, administration time, administration route and excretion rate, treatment period, factors including drugs used simultaneously, and other factors well known in the medical field. Thus, although the dosage regimen may vary widely, it is important to take all these factors into consideration and administer the minimum amount that provides maximum effect without side effects, which can be easily determined by those skilled in the art using standard methods.
[0068] Another aspect of the present invention relates to a health functional food comprising a Faecalibacterium strain or extracellular vesicles (EVs) derived from a Faecalibacterium strain. The Faecalibacterium strain may be a live or killed bacterium. The extracellular vesicles are preferably extracellular vesicles derived from Faecalibacterium prausnitzii EB-FPDK3, F.prausnitzii EB-FPDK9, F.prausnitzii EB-FPDK11, and F.prausnitzii EB-FPYYK1 strains. The health functional food of the present invention can be used for the prevention or improvement of cancer.
[0069] The health functional food of the present invention includes all forms such as nutraceutical foods, nutritional supplements, health foods, food additives, and feeds.
[0070] The above-mentioned type of health functional food can be prepared in various forms according to conventional methods known in the art. General foods, including but not limited to beverages (including alcoholic beverages), fruits and processed foods thereof, fish, meat and processed foods thereof, breads and noodles, fruit juices, various drinks, cookies, candies, dairy products, edible vegetable oils and fats, margarine, vegetable proteins, retort foods, frozen foods, various sauces, etc., can be prepared by adding extracellular vesicles derived from the F. prausnitzii EB-FPDK3 strain, F. prausnitzii EB-FPDK9 strain, F. prausnitzii EB-FPDK11 strain, and F. prausnitzii EB-FPYYK1 strain of the genus F. prausnitzii.
[0071] In addition to the above, the health functional food of the present invention may contain various nutrients, vitamins, electrolytes, flavorings, colorants, pectinic acid, salts of pectinic acid, alginic acid, salts of alginic acid, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohol or carbonation agents, etc.
[0072] Another aspect of the present invention relates to a veterinary composition for preventing or treating cancer, comprising a Faecalibacterium strain or extracellular vesicles (EVs) derived from a Faecalibacterium strain, and a physiologically acceptable carrier or excipient. Here, the animal may refer to, but is not limited to, pets such as dogs, cats, guinea pigs, hamsters, rats, mice, ferrets, rabbits, etc. The veterinary composition may be a feed additive.
[0073] Another aspect of the present invention relates to a method for treating cancer in a subject, comprising administering to the subject a therapeutically effective amount of a Faecalibacterium strain described herein or extracellular vesicles derived from a Faecalibacterium strain.
[0074] Another aspect of the present invention provides novel Faecalibacterium sp. strains EB-FPDK3 (KCCM12619P), EB-FPDK9 (KCCM12620P), EB-FPDK11 (KCCM12621P), and EB-FPYYK1 strain 1 (KCCM12622P), each of which was deposited at the Korea Institute of Bioscience and Biotechnology, Biological Resources Center on November 1, 2019.
[0075] The present invention will be described in detail below with reference to examples. However, these examples are merely illustrative of the present invention, and the content of the present invention is not limited to these examples.
[0076] Working Example Example 1: Faecalis bacterium prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11 and F. prausnitzii Isolation and identification of EB-FPYYK1 strain 1.1. Strain isolation and identification To isolate Faecalibacterium strains from feces of a healthy Korean female (7 years old, BMI 19.9), the strains were cultured in an anaerobic chamber under strict anoxic conditions (5% H2, 5% CO2, and 90% N2) using brain heart infusion medium (YBHI) supplemented with 0.5% yeast extract, 0.1% D-cellobiose, and 0.1% D-maltose (Difco, Detroit, USA) according to the Martin method, and then EOS (extremely oxygen sensitive) strains were selected and isolated (Martin et al., 2017). The standard strain, Faecalibacterium prausnitzii A2-165, was provided by DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen) and used in the study.
[0077] 1.2.Microscopic Observation To confirm whether the isolated strains were Faecalibacterium spp. strains, the isolated strains were observed under a microscope, and the results are shown in Figure 1. As shown in Figure 1, when the standard strain Faecalibacterium prausnitzii A2-165 standard strain and the Faecalibacterium prausnitzii EB-FPDK3, EB-FPDK9, EB-FPDK11, and EB-FPYYK1 isolated strains of the present invention were observed at a magnification of 1,000 times, all of the strains were observed to have straight or curved rod-shaped cells.
[0078] 1.3. PCR analysis To confirm whether the isolated strain was a Faecalibacterium strain, the isolated strain was subjected to PCR analysis using the FP-specific primers (SEQ ID NO: 1 and SEQ ID NO: 2) in Table 1 below, and the results are shown in Figure 2. In Figure 2, lane M is the DNA size marker, lane 1 is the positive control group (A2-165), lanes 2 to 5 are the isolated strains, and lane 6 is the result for the negative control group (distilled water).
[0079] As shown in Figure 2, it can be confirmed that the isolated strains of the present invention, i.e., F. prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 strains, showed the same band pattern as the standard strain F. prausnitzii A2-165.
[0080] [Table 1]
[0081] 1.4. RAPD (Random Amplified Polymorphic DNA) analysis To verify the similarity of the isolated F. prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 strains to the previously reported standard strain F. prausnitzii A2-165, a type of molecular typing, was performed using RAPD. For this purpose, genomic DNA extracted from the cells was amplified using the universal primers in Table 2 below, and then electrophoresed on a 1% agarose gel for 1 hour and 30 minutes. The DNA fragmentation patterns were compared on a UV perforator, and the results are shown in Figure 3.
[0082] [Table 2]
[0083] As can be seen from Figure 3, the Faecalibacterium prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 strains of the present invention showed different RAPD band patterns when compared to the standard strain Faecalibacterium prausnitzii A2-165. It is known that the RAPD band pattern of Faecalibacterium prausnitzii differs depending on the species, and it has been confirmed that the Faecalibacterium prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 strains of the present invention belong to the same species as the Faecalibacterium prausnitzii A2-165 type strain, but are different strains from each other.
[0084] 1.5.Total length 16S Phylogenetic tree based on rRNA gene sequences Tree analysis To analyze the full-length 16S rRNA gene sequences of the isolated F. prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 strains, the 16S rRNA genes were amplified using the 27F and 1492R primers in Table 3 below, and the sequences were determined using a 3730x1 DNA analyzer. A complete rRNA sequence database was created by collecting the 16S rRNA gene sequences of eight strains, including Faecalibacterium prausnitzii EB-FPYYK1, EB-FPDK3, EB-FPDK9, and EB-FPDK11, the previously published Faecalibacterium prausnitzii strains (A2-165, ATCC27766, ATCC27768), and the Ruminococcus albus DSM20455 strain belonging to the Ruminococcaceae family. The homology and query coverage were calculated using the Nucleotide-Nucleotide BLAST 2.9.0+ program and are shown in Table 4. Phylogenetic analysis was also performed based on the 16S rRNA gene sequences of the eight strains. Phylogenetic analysis was performed using MEGA-X. A phylogenetic tree was constructed by the neighbor-joining method using 1000 bootstraps and is shown in Figure 4(A). Average nucleotide identity (ANI) values were used to assess evolutionary distances by applying the pyani v0.2.7 program with the -m ANIb setting.The whole or draft genome sequences of Faecalibacterium prausnitzii A2-165 (RefSeq assembly accession: GCF_000162015.1), Faecalibacterium prausnitzii ATCC27766 (RefSeq assembly accession: GCF_003324115.1), Faecalibacterium prausnitzii ATCC27768 (RefSeq assembly accession: GCF_003324185.1), and Ruminococcus albus DSM20455 (RefSeq assembly accession: GCF_000179635.2) were downloaded from the NCBI Genome Database (https: / / www.ncbi.nlm.nih.gov / genome / ). A phylogenetic tree was constructed using the 16S rRNA gene sequences of other strains of the same species, as shown in Figure 4(B).
[0085] [Table 3]
[0086] [Table 4]
[0087] As shown in Figures 4(A) and 4(B) and Table 4, in the case of the Faecalibacterium prausnitzii EB-FPYYK1 strain, it was confirmed that the base sequence of the 16S rRNA gene had 99.735% identity and 100% query coverage with the already published Faecalibacterium prausnitzii A2-165 strain, 97.95% identity and 100% query coverage with the ATCC27768 strain, and 86.868% identity and 100% query coverage with the Ruminococcus albus DSM20455 strain belonging to the Ruminococcaceae family. The EB-FPDK3 strain of Faecalibacterium prausnitzii was confirmed to have 98.676% identity with the A2-165 strain, 98.082% identity with the F. prausnitzii ATCC27768 strain, and 86.623% identity with the R. albus DSM20455 strain. The EB-FPDK9 strain was confirmed to have 97.95% identity with the A2-165 strain, 99.603% identity with the ATCC27768 strain, and 86.623% identity with the R. albus DSM20455 strain. In the case of the EB-FPDK11 strain, it was confirmed that it has 98.613% identity with the F. prausnitzii A2-165 standard strain, 97.82% identity with the F. prausnitzii ATCC27768 strain, and 86.82% identity with the DSM20455 strain. In other words, as a result of analyzing the phylogenetic tree showing the evolutionary relationship by 16S rRNA gene base sequence analysis, it was confirmed that the F. prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 strains are genetically strains belonging to F. prausnitzii.
[0088] The Faecalibacterium prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 strains of the present invention isolated from human feces were identified through biochemical methods (API) and molecular biological methods (16S rRNA sequence analysis, 16S rRNA BLAST analysis, RAPD) using Faecalibacterium prausnitzii (A2-165) as a control, and were confirmed to be safe strains capable of probiotic function through the antibiotic resistance test described below. Based on these results, the isolated F. prausnitzii strains were named F. prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 and were deposited at the Korea Institute of Bioscience and Biotechnology under the accession numbers KCCM12619P, KCCM12620P, KCCM12621P, and KCCM12622P, respectively.
[0089] Example 2: Faecalibacterium prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11 and F. prausnitzii Analysis of the mycological characteristics and safety of the EB-FPYYK1 strain 2.1. Confirmation of antimicrobial susceptibility of isolated strains To examine the antimicrobial susceptibility of the Faecalibacterium prausnitzii strains isolated as described above, the minimum inhibitory concentration (MIC) of the anaerobic antimicrobial agents (piperacillin-tazobactam (PTZ), ceftizoxime (CTZ), chloramphenicol (CHL), clindamycin (CLI), meropenem (MEM), moxifloxacin (MXF), metronidazole (MTZ), and ciprofloxacin (CIP)) was determined by the broth microdilution method of the Clinical & Laboratory Standard Institute (CLSI) guidelines (CLSI, 2017), and the results are shown in Table 5 below.
[0090] [Table 5]
[0091] As can be seen from Table 5, the Faecalibacterium prausnitzii strains of the present invention showed different resistance patterns, with all strains being sensitive to metronidazole, and all strains being resistant to the fluoroquinolone antibiotics moxifloxacin and ciprofloxacin. Resistance to fluoroquinolone antibiotics is a resistance that exists in the same Faecalibacterium prausnitzii and is considered to be an intrinsic resistance. Furthermore, genes encoding antibiotic resistance genes were examined on the full-length genomes of the Faecalibacterium prausnitzii EB-FPYYK1, EB-FPDK3, EB-FPDK9, and EB-FPDK11 strains of the present invention based on MEGARes (https: / / megares.meglab.org / ), an antibiotic resistance gene database. The results are shown in Table 6 below.
[0092] [Table 6]
[0093] As can be seen from Table 6, in the case of the standard strain of Faecalibacterium prausnitzii A2-165, the aminoglycoside O-nucleotidyltransferases gene was detected. In addition, in the case of the Faecalibacterium prausnitzii EB-FPYYK1, EB-FPDK3, EB-FPDK9, and EB-FPDK11 strains of the present invention, the aminoglycoside O-nucleotidyltransferases, 23S rRNA methyltransferases, 23S rRNA methyltransferases, and tetracycline resistance ribosomal protection proteins genes were detected, respectively. The antibiotic resistance genes detected through the MEGARes database were analyzed using Resfinder, a bioinformatics-based antibiotic resistance gene detection program. (https: / / cge.cbs.dtu.dk / services / ResFinder / ) These results confirmed that antibiotic resistance genes do not appear uniformly in Faecalibacterium prausnitzii strains, but appear differently in each strain.
[0094] As antibiotic resistance genes were detected in the Faecalibacterium prausnitzii strain, further investigations were performed using the PlasmidFinder (https: / / cgd.cbs.dtu.dk / services / PlasmidFinder / ) and Mobile Element Finder (cge.cbs.dtu.dk / services / MobileElementFinder) programs. PlasmidFinder program was used to check for the presence or absence of plasmids on the full-length genomes of the Faecalibacterium prausnitzii EB-FPYYK1, EB-FPDK3, EB-FPDK9, and EB-FPDK11 strains of the present invention, and it was confirmed that no plasmids were detected. In addition, mobile genetic elements were checked on the full-length genomes of the Faecalibacterium prausnitzii EB-FPYYK1, EB-FPDK3, EB-FPDK9, and EB-FPDK11 strains of the present invention using the Mobile Element Finder program, and it was confirmed that no transposons were detected. From the results, it was confirmed that the detected antibiotic resistance gene was not transferred to other strains, and therefore, it was confirmed that the F. prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 strains of the genus Faecalibacterium prausnitzii according to the present invention are safe strains.
[0095] 2.3. Hemolytic activity of isolated strains analysis of activity) and virulence factors To verify the safety of the isolated F. prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 strains, we evaluated whether they retained hemolytic activity. To this end, the strains were cultured on blood agar medium prepared by adding 5% w / v defibrinated cryp blood to tryptic soy agar (17.0 g / L casein pancreatic digest, 3.0 g / L soybean pancreatic digest, 2.5 g / L dextrose, 5.0 g / L sodium chloride, 2.5 g / L potassium phosphate, and 15 g / L agar), and the results are shown in Figure 5. As can be seen from Figure 5, the F. prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 strains of the present invention did not exhibit β-hemolysis (completely transparent areas around the colony), which is associated with pathogenicity.
[0096] The VFDB (reference database for bacterial virulence factors, http: / / www.mgc.ac.cn / VFs), genes encoding virulence factors were searched for in the full-length genomes of the Faecalibacterium prausnitzii strains of the present invention, EB-YYK1, EB-FPDK3, EB-FPDK9, and EB-FPDK11. The Virulence Factor Database (VFDB) is a comprehensive online resource for filtering information on virulence factors of bacterial pathogens, providing a deep look at the major virulence factors of the most well-characterized bacterial pathogens. The VFDB database used in the analysis contains 3,688 and 32,772 sequence data related to virulence. For the analysis, the analysis conditions were a minimum of 80% protein identity, a minimum of 80% coverage, and a minimum alignment length of 50 bp. As a result of the analysis, no virulence factors were detected in the Faecalibacterium prausnitzii strains of the present invention, EB-FPYYK1, EB-FPDK3, EB-FPDK9, and EB-FPDK11. Furthermore, the VirulenceFinder ( https: / / cge.cbs.dtu.dk / services / VirulenceFinder / ) were examined for virulence factor genes. VirulenceFinder is a database consisting of the genome sequences of four well-known pathogens (E. coli, Enterococcus, Listeria, and Staphylococcus aureus). As a result of the analysis, genes related to E. coli shiga toxin gene, S. aureus exoenzyme genes, and host immune alteration or evasion genes and toxin genes were not detected on the full-length genome of the Faecalibacterium prausnitzii EB-FPYYK1, EB-FPDK3, EB-FPDK9, and EB-FPDK11 strains of the present invention. Overall, it can be seen that the Faecalibacterium prausnitzii EB-FPYYK1, EB-FPDK3, EB-FPDK9, and EB-FPDK11 strains of the present invention are harmless in the human body.
[0097] 2.4. Confirmation of short-chain fatty acids (SCFAs) production ability of Faecalibacterium prausnitzii strain Short chain fatty acids (SCFAs), such as butyrate, acetate, and propionate, are metabolic products produced by intestinal bacteria and play an important role in the host's energy metabolism. They are signaling mediators that act on G protein-coupled receptors (GPR41 and GPR43) and are involved in energy balance.
[0098] Short-chain fatty acids (SCFAs) decrease intestinal motility and increase intestinal transit rate through GPR41 in enteroendocrine cells. This induces PYY (peptide YY) secretion, which reduces energy intake and prevents obesity. In addition, GPR43 by short-chain fatty acids increases satiety by inducing GPL-1 (glucagon-like peptide 1) and increasing insulin sensitivity, and GPR43 activation suppresses insulin signaling from adipose tissue to prevent fat accumulation. Short-chain fatty acids (SCFAs) can improve glucose metabolism and activate intestinal gluconeogenesis (IGN), which can reduce food intake via the gut-brain neural circuit.
[0099] To confirm the change in functional metabolites of Faecalibacterium prausnitzii, the culture was cultured in a test tube, and the change in the content of major short-chain fatty acids (butyric acid and acetic acid) in the culture medium was analyzed by gas chromatography (GC). For this, the culture medium was centrifuged at 12,000×g for 5 minutes to collect the supernatant. The supernatant was filtered using a 0.2 μm syringe filter before being used for analysis. A gas chromatograph (Agilent 7890N) equipped with a FFAP column (30 m×0.320 mm, 0.25 μm phase) was used. The conditions were as shown in Table 7. The analysis results are shown in Table 8 below.
[0100] [Table 7]
[0101] [Table 8]
[0102] As can be seen from the results of Table 8, the Faecalibacterium prausnitzii EB-FPDK strains of the present invention showed different short-chain fatty acid production / consumption abilities. In particular, the Faecalibacterium prausnitzii A2-165 standard strain and the EB-FPYYK1, EB-FPDK9 and EB-FPDK11 strains were confirmed to have similar acetate consumption and butyrate production, respectively, and the EB-FPDK3 strain had the lowest butyrate production among the five strains, but the acetate consumption was the highest. Faecalibacterium prausnitzii is known as a representative butyrate-producing bacterium, and butyrate is synthesized from acetate in these metabolic pathways, resulting in acetate consumption.
[0103] Example 3: Isolation of extracellular vesicles from Faecalis prausnitzii strain To obtain extracellular vesicles (EVs) from Faecalibacterium prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1, the culture solutions of Faecalibacterium prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 were centrifuged at 10,000 × g and 4°C for 20 minutes, and the supernatants were collected and filtered through 0.45 μm and 0.22 μm filters. The filtered supernatant was centrifuged at 150,000×g and 4° C. for 2 hours to obtain a pellet, which was then dissolved in sterile saline (PBS) and subjected to protein quantification before being used in efficacy tests.
[0104] The isolated extracellular vesicles were observed under an electron microscope (Zeiss, Germany) (150,000×), and the results are shown in Figure 6. As shown in Figure 6, the extracellular vesicles (EVs) of the present invention's F. prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 strains were spherical, and it could be confirmed that the approximate size was within the range of 20 to 300 nm (scale bar 500 nM).
[0105] Example 4: Anticancer effect of aPD-1 immunotherapy in combination with live Faecalibacterium prausnitzii EB-FPDK3, EB-FPDK9, EB-FPDK11, and EB-FPYYK1 in a melanoma allograft mouse animal model 4.1. Strain samples The Faecalibacterium prausnitzii A2-165 standard strain (control group) and Faecalibacterium prausnitzii EB-FPDK3 strain (KCCM12619P), EB-FPDK9 strain (KCCM12620P), EB-FPDK11 strain (KCCM12621P), and EB-FPYYK1 strain (KCCCM12622P) viable cells were used in this experiment at 1 × 10 8 The cells were prepared at a concentration of CFU / 150 μL of PBS (25% glycerol, 0.05% cysteine / PBS).
[0106] Animal testing Animal experiments were performed in accordance with the Animal Use and Care Protocol of the IACUC (Institutional Animal Care and Use Committee). For cancer induction, 8-week-old female C57BL / 6 mice were purchased and allowed to adapt for one week, after which they were housed for five weeks. The housing environment was maintained at a constant temperature (22°C) and relative humidity (40-60%), with light and dark cycles controlled on a 12-hour cycle.
[0107] To establish a syngeneic mouse anti-cancer animal model, mouse-derived melanoma cells (B16-F10) were used.
[0108] The allograft model is a technique in which a mouse cell line grown in vitro is transplanted into an actual mouse and grown there. Since the same host and cell line are used, there is no risk of tumor rejection.
[0109] After one week of acclimation, the mice were pretreated with the antibiotics shown in Table 9 for one week.
[0110] [Table 9]
[0111] Next, 2 × 10 4 B16-F10 cells were subcutaneously injected (SC) into the thigh of a mouse together with 100 μL of Matrigel. The animal experiment scheme in this example is shown in FIG. 7a.
[0112] 4.3. Sample administration and experimental group setting Each drug shown in Table 10 below was orally administered to mice every day for two weeks. As a positive control group, anti-PD1 antibody was orally administered at 250 μg / 600 μL / head.
[0113] Cancer cells began to appear on day 6, and from this time point, F. prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 strains were cultured for 10 min at 4 °C. 8 CFU was orally administered daily. From the sixth day, 250μg of aPD-1 antibody was intraperitoneally injected every four days. In this case, the aPD-1 antibody used was InVivoMab anti-mouse PD-1 (RMP1-14), catalog #BE0146, from BioXCell. The antibody was diluted to a concentration of 250μg / 100μL using InVivoPure pH7.0 Dilution Buffer, catalog #IP0070.
[0114] During tumor growth, mice were weighed twice a week and monitored daily, and tumor size was monitored every other day using a computerized caliper starting on day 6, when cancer cells began to appear (see Figure 8).
[0115] Tumor volume was calculated by measuring the two diameters (longest and shortest diameters) of each tumor according to the following formula:
[0116]
number
[0117] [Table 10]
[0118] As shown in Figures 8 to 10, the tumor size was significantly reduced in the groups orally administered live Faecalibacterium prausnitzii EB-FPDK3, EB-FPDK9, EB-FPDK11, and EB-FPYYK1 bacteria, compared to the control group that received the allogeneic transplant of B16-F10 cells. The tumor size in the normal control group was 726.8 ± 66.7 mm. 3 In comparison, the tumor size in the aPD-1-treated group was 419.5 ± 80.43 mm 3 In the aPD-1 and EB-FPDK3, EB-FPDK9, EB-FPDK11, and EB-FPYYK1 combination treatment groups, the mean tumor size was 400.6 ± 67.45 mm, respectively. 3 , (P<0.01), 455.7±67.67 mm 3 , (P<0.05), 190.7±42.5mm 3 , (P<0.001), 355.6±50.47mm 3 In particular, the aPD-1 and EB-FPDK11 combination treatment group showed the greatest anti-cancer effect, with a 74% decrease compared to the normal control group.
[0119] Example 5: Anticancer effect of combined administration of aPD-1 immunotherapy and Faecalibacterium prausnitzii EB-FPDK3, EB-FPDK9, EB-FPDK11, and EB-FPYYK1-derived extracellular vesicles (EVs) in a melanoma allograft mouse animal model Referring to Figure 7b, starting from day 6 when cancer cells began to appear, 250μg of aPD-1 antibody and 100μg of extracellular vesicles (EVs) derived from F. prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 strains were intraperitoneally injected at 4-day intervals. The aPD-1 antibody used was InVivoMab anti-mouse PD-1 (RMP1-14), catalog #BE0146 from BioXCell. It was diluted to a concentration of 250μg / 100μL using InVivoPure pH7.0 Dilution Buffer, catalog #IP0070.
[0120] The tumor size was monitored every two days from the time the tumor was measured, and the tumor size was calculated according to Formula 1, and the results are shown in the graph in Figure 11. The extracellular vesicles were tested for their efficacy alone or in the presence or absence of anti-PD1 in mouse tumor models.
[0121] Referring to Figures 11 and 13, it was confirmed that the tumor size was significantly smaller in the groups orally administered extracellular vesicles (EVs) derived from F. prausnitzii EB-FPDK3, F. prausnitzii EB-FPDK9, F. prausnitzii EB-FPDK11, and F. prausnitzii EB-FPYYK1 strains compared to the control group allogeneically transplanted with B16-F10 cells. The tumor size in the normal control group was 570.4 ± 160.7 mm. 3 In comparison, the tumor size in the aPD-1-treated group was 378.1 ± 128 mm 3 In the groups administered aPD-1 in combination with EB-FPDK3 EV, EB-FPDK9 EV, EB-FPDK11 EV, and EB-FPYYK1 EV, the mean mean was 165.6 ± 57.54 mm 3 , 152.7±40.44mm 3, 230.2±83.91mm 3 , 237.1±73.95mm 3 In particular, the aPD-1 and EB-FPDK9 combination treatment group showed the highest anti-cancer effect, with tumor size reduced by approximately 73% compared to the normal control group.
[0122] Referring to Figure 12, after sacrificing the mice, the tumors were excised and weighed. The average tumor weight of the normal control group was 2.8±0.6622g, while the aPD-1 group had a tumor weight of 1.89±0.5806g, which was not significantly different. However, the EB-FPDK3 EV, EB-FPDK9 EV, and EB-FPDK11 EV groups, which were administered PD-1 and EB-FP EV in combination, showed a significant reduction compared to the normal control group. Compared to the normal control group tumor weight of 2.8±0.6622g, the tumor weight of each group was significantly reduced to EB-FPDK3 EV: 0.7696±0.2281g (P<0.01), EB-FPDK9 EV: 0.8688±0.2224g (P<0.05), and EB-FPDK11: 0.7409±0.2423g (P<0.05).
[0123] As described above, the present inventors confirmed the effect of Faecalibacterium sp.-derived extracellular vesicles (EVs) and anti-PD1 immune checkpoint inhibitors on cancer cell growth and metastasis in vivo, and confirmed that tumor size and weight were effectively reduced when Faecalibacterium sp.-derived extracellular vesicles (EVs) and anti-PD1 immune checkpoint inhibitors were injected into tumor-implanted mice (see Figures 11 and 12). Therefore, the pharmaceutical composition of the present invention has a significantly superior tumor growth inhibitory effect compared to administration of anti-PD1 alone, and can be usefully used as a pharmaceutical composition for preventing or treating cancer.
[0124] Example 6: Wound healing assay using HT29 cells and B16-F10 healing Assay To investigate the anticancer activity of extracellular vesicles derived from the Faecalibacterium prausnitzii strain of the present invention, a wound healing activity experiment was carried out.
[0125] HT29 human colon cancer cells were cultured in McCoy's medium containing 10% FBS and 1% gentamicin at 5% CO2 and 37℃. HT29 colon cancer cells were dispensed into a 6-well cell culture plate and cultured to confluence. Then, a pipette tip was used to make a consistent scratch on the 6-well plate. Then, EB-FPDK3, EB-FPDK9, EB-FPDK11, and EB-FPYYK1 EVs were treated at 1 or 10μg / mL for 24 hours and observed under a microscope. The cell area was calculated using the Image J program.
[0126] 14a and 14b, in the wound healing experiment using HT29 cells, EB-FPDK3 EV at 1 μg / mL and 10 μg / mL reduced metastasis by 25.97% and 55.25%, respectively, compared to the normal control group. In addition, a significant reduction was observed in the group treated with 10 μg / mL, with P<0.05. In the experimental groups treated with EB-FPDK9 EV at 1 μg / mL and 10 μg / mL, a 66.91% and 58.95% reduction in metastasis was observed, respectively, compared to the normal control group. A significant reduction was observed in both concentrations, with P<0.05. In the experimental groups treated with EB-FPDK11 EV at concentrations of 1 μg / mL and 10 μg / mL, a 54.48% and 49.45% reduction in metastasis was observed compared to the normal control group, with both concentrations showing significant reductions (P<0.05, P<0.1, respectively).Finally, in the experimental groups treated with EB-FPYYK1 EV at concentrations of 1 μg / mL and 10 μg / mL, a 49.45% and 59.4% reduction in metastasis was observed compared to the normal control group, with both concentrations showing significant reductions (P<0.1, P<0.05, respectively).
[0127] Example 7: Faecalibacterium prausnitzii EB-FPDK9 strain or EB-FPDK9-derived extracellular vesicles (EB-FPDK9) in a melanoma allograft mouse animal model Anti-cancer effect of EVs administration 7.1.Experimental Method Five-week-old C57BL / 6 female mice were purchased and, after a one-week acclimation period, the mice were inoculated with melanoma cell line B16F10 at 5 × 10 5 The cells were then injected subcutaneously to create syngenic mice. All mice were orally administered 250μL of a mixture of the antibiotics ampicillin 15mg / mL, neomycin 15mg / mL, metronidazole 10mg / mL, and vancomycin 7.5mg / mL for two days.
[0128] As a positive control group, anti-PD-1 immunosuppressant (αPD-1) was intraperitoneally administered at 200 μg / 200 μL once every 3 days from the 7th day after tumor implantation. Faecalibacterium prausnitzii EB-FPDK9 strain was administered at 1 × 10 8 CFU was orally administered twice every three days, and 50 μg of Faecalibacterium prausnitzii EB-FPDK9 EVs was administered via the tail vein (see Figure 15).
[0129] The tumor size was measured using a ruler once every three days, and the tumor size was calculated as the long axis × short axis squared × 0.5 (mm 3 ) was calculated.
[0130] 7.2.Experimental Results Tumor size was measured and followed from day 7 after B16F10 cell line implantation. On day 19, mice were sacrificed and tumor weight was measured. From day 13, tumor growth was suppressed in the experimental groups administered Faecalibacterium prausnitzii EB-FPDK9 strain and Faecalibacterium prausnitzii EB-FPDK9 EVs, including the αPD-1 experimental group as a positive control, compared to the normal control group.
[0131] Referring to FIG. 16, the tumor size of the normal control group on the 19th day, which was the day the mice were sacrificed, was 260.4±64.33 mm. 3 The tumor size in the EB-FPDK9-treated group was 135.6 ± 56.46 mm compared with 135.6 ± 56.46 mm 3 The tumor size in the EB-FPDK9 EVs-treated group was 53.26.51 mm 3The decrease was statistically significant at approximately 80%.
[0132] Referring to Figure 17, compared to the normal control group, tumor weight was significantly reduced in the Faecalibacterium prausnitzii EB-FPDK9 and Faecalibacterium prausnitzii EB-FPDK9 EVs-administered groups, including the positive control group αPD-1. In particular, the Faecalibacterium prausnitzii EB-FPDK9 EVs-administered group showed a statistically significant decrease.
[0133] When compared with the tumor size and weight results of the αPD-1-treated group, similar levels were observed in the Faecalibacterium prausnitzii EB-FPDK9 strain or Faecalibacterium prausnitzii EB-FPDK9 EVs-treated groups (see Figures 16 and 17), demonstrating that the sole administration of Faecalibacterium prausnitzii EB-FPDK9 strain and Faecalibacterium prausnitzii EB-FPDK9 EVs has the same anti-cancer efficacy as αPD-1.
[0134] The specific embodiments disclosed in this specification are for illustrating preferred embodiments of the present invention and should not be construed as limiting the present invention. The present invention can be implemented with various modifications and changes without departing from the spirit and scope of the present invention, and these facts will be obvious to those skilled in the art. The protection scope of the present invention should be defined by the appended claims, and it is intended that such various modifications and changes are included in the protection scope of the present invention.
[0135] [Accession number] Depository institution name: Korea Institute of Bioscience and Biotechnology Accession number: KCCM12619P(EB-FPDK3) Entrustment date: November 1, 2019 Depository institution name: Korea Institute of Bioscience and Biotechnology Accession number: KCCM12620P(EB-FPDK9) Entrustment date: November 1, 2019 Depository institution name: Korea Institute of Bioscience and Biotechnology Accession number: KCCM12621P (EB-FPDK11) Entrustment date: November 1, 2019 Depository institution name: Korea Institute of Bioscience and Biotechnology Accession number: KCCM12622P (EB-FPYYK1) Entrustment date: November 1, 2019
[0136] [ka]
[0137] [ka]
[0138] [ka]
[0139] [ka]
Claims
1. A pharmaceutical composition for preventing or treating cancer, comprising extracellular vesicles (EVs) derived from a Faecalibacterium strain and a pharma- ceutically acceptable carrier or excipient.
2. The pharmaceutical composition for preventing or treating cancer according to claim 1, wherein the Faecalibacterium sp. strain is a Faecalibacterium prausnitzii strain.
3. The pharmaceutical composition for preventing or treating cancer according to claim 1, characterized in that the Faecalibacterium genus strain is Faecalibacterium prausnitzii EB-FPDK3 strain (KCCM12619P), F. prausnitzii EB-FPDK9 strain (KCCM12620P), F. prausnitzii EB-FPDK11 strain (KCCM12621P), or F. prausnitzii EB-FPYYK1 strain (KCCM12622P).
4. The pharmaceutical composition for preventing or treating cancer according to claim 1, wherein the extracellular vesicles (EVs) derived from the Faecalibacterium sp. strain have an average diameter of 20 to 300 nm.
5. 2. The pharmaceutical composition for preventing or treating cancer according to claim 1, wherein the cancer is any one selected from the group consisting of colorectal cancer, lung cancer, small cell lung cancer, gastric cancer, liver cancer, blood cancer, bone cancer, pancreatic cancer, skin cancer, head or neck cancer, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, perianal cancer, colon cancer, breast cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, Hodgkin's disease, esophageal cancer, small intestine cancer, endocrine gland cancer, thyroid cancer, parathyroid cancer, adrenal gland cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, chronic or acute leukemia, lymphocytic lymphoma, bladder cancer, kidney cancer, ureteral cancer, renal cell carcinoma, renal pelvic cancer, CNS tumor, primary CNS lymphoma, spinal cord tumor, brain stem glioma, and pituitary adenoma.
6. The pharmaceutical composition for preventing or treating cancer according to claim 1 , further comprising a chemical anti-cancer agent or an immunological anti-cancer agent.
7. 7. The pharmaceutical composition for preventing or treating cancer according to claim 6, wherein the immunological anticancer agent is at least one selected from the group consisting of anti-PD1, anti-PDL1, anti-CTLA, anti-Tim3, and anti-LAG3.
8. The pharmaceutical composition for preventing or treating cancer according to claim 6, characterized in that the extracellular vesicles (EVs) derived from a Faecalibacterium sp. strain and the chemical anticancer agent or immunoanticancer agent are administered simultaneously in a single dosage form, or simultaneously or sequentially in separate dosage forms.
9. A pharmaceutical composition for preventing or treating cancer, comprising a Faecalibacterium strain and a pharma- ceutically acceptable carrier or excipient.
10. The pharmaceutical composition for preventing or treating cancer according to claim 9, wherein the Faecalibacterium strain is a live or killed bacterium.
11. 10. The pharmaceutical composition for preventing or treating cancer according to claim 9, wherein the Faecalibacterium strain is a Faecalibacterium prausnitzii strain.
12. The pharmaceutical composition for preventing or treating cancer according to claim 9, characterized in that the Faecalibacterium genus strain is Faecalibacterium prausnitzii EB-FPDK3 strain (KCCM12619P), F. prausnitzii EB-FPDK9 strain (KCCM12620P), F. prausnitzii EB-FPDK11 strain (KCCM12621P), or F. prausnitzii EB-FPYYK1 strain (KCCM12622P).
13. A health functional food for preventing or improving cancer, comprising extracellular vesicles (EVs) derived from a Faecalibacterium strain or a Faecalibacterium strain, and a physiologically acceptable carrier or excipient.
14. A veterinary composition for preventing or treating cancer, comprising extracellular vesicles (EVs) derived from a Faecalibacterium strain or a Faecalibacterium strain, and a pharma- ceutically acceptable carrier or excipient.
Citation Information
Patent Citations
Faecalibacterium sp. microbe and anticancer composition comprising same
WO2020197362A1
Compositions and methods for treating diseases and disorders using oscillospiraceae microbial extracellular vesicles
WO2021252877A1
Novel picalibacterium prosnich EB-FPDK9 strain and uses thereof
WO2021261631A1
Novel faecalibacterium prausnitzii strain EB-FPDK11 and use thereof
WO2021261632A1
Association of a faecalibacterium prausnitzii strain and Anti-PD-1, Anti-PD-l1 or Anti-CTLA-4 antibodies for the treatment of cancer
WO2023062222A1
